ALTSTATION.IO

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$785.65

Change

+2.46%

Market Cap

$83.05B

Avg Volume

967.8K

Company Overview

Regeneron Pharmaceuticals, Inc. is a biotechnology company based in Tarrytown, New York. They discover and develop medicines for various diseases, ranging from eye conditions to cancer and rare diseases. Key products include EYLEA for eye conditions, Dupixent for asthma and dermatitis, and Libtayo for skin cancers. Their customers include hospitals, clinics, and specialty pharmacies, as well as patients requiring these treatments.

Regeneron holds a strong position in the biotechnology sector, often regarded as a market leader, particularly in ophthalmology and immunology. Their R&D prowess and an established portfolio of drugs give them a competitive edge. However, they face threats from competitors like Amgen and Genentech, especially with the rising focus on gene therapies and biosimilars. The landscape is shifting as more companies invest in advanced biotechnologies, increasing competition and pressure on pricing.

Currently, Regeneron is in a growth phase. Recent milestones include successful Phase 3 trials for new indications of existing drugs and collaborations with firms like Bayer to expand their product offerings. Their pipeline is robust, with multiple candidates in late-stage development, positioning them well for future revenue growth. Overall, Regeneron is leveraging its strengths in innovation while navigating an increasingly competitive landscape.

Key Financials

Market Cap

$83.05B

Revenue

$14.34B

EBITDA

$4.25B

Gross Margin

44.6%

Profit Margin

31.4%

Revenue Growth

2.5%

Total Cash

$8.61B

Total Debt

$3.45B

Free Cash Flow

$3.32B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

18.94

Forward P/E

15.02

Beta

0.41

52-Week High

$821.11

52-Week Low

$476.49

EPS

$41.47

50-Day Avg

$758.23

200-Day Avg

$622.62

Price/Book

2.58

Technical Analysis

Over the past 52 weeks, Regeneron Pharmaceuticals, Inc. (REGN) has shown a strong upward trend, with a gain of 14.4%, indicating solid bullish momentum. Key resistance is identified at approximately $800, where the stock has faced rejection multiple times, while support is established at around $700, evident during pullbacks in the previous months. The price has demonstrated a series of higher lows and higher highs, contributing to an ascending channel, which suggests continued positive sentiment. Recently, the momentum has picked up, with notable gains occurring over the last few weeks, including a push through the $780 level. The current price of $785.65 is comfortably positioned within the upper range of its 52-week performance, indicating that the stock remains well-above the key support level and is approaching the historical highs, which may suggest further upward potential if the momentum continues.

Recent News and Developments

Here are the latest news and developments for Regeneron Pharmaceuticals, Inc

(REGN) stock in the past week (January 31, 2026, to February 7, 2026):

1. Regeneron Reports Strong Q4 2025 Earnings, Driven by Key Product Growth

Regeneron Pharmaceuticals announced its fiscal fourth-quarter 2025 earnings on January 30, 2026, reporting a 3% year-over-year increase in revenue to $3.88 billion and an EPS of $11.44, surpassing analyst estimates. This growth was significantly boosted by strong sales performances from key products, with Dupixent sales climbing 32%, Libtayo sales increasing 13% on a constant-currency basis, and Eylea HD sales in the U.S. rising by 66%.

2. Analysts Raise Price Targets and Reiterate “Outperform” on Regeneron Stock

Following the earnings report, several analyst firms adjusted their outlook for Regeneron. On February 2, 2026, Oppenheimer reiterated an “Outperform” rating for REGN and increased its price target from $750.00 to $865.00. Similarly, JP Morgan set a new price target of $950.00 for Regeneron on February 2, 2026, while maintaining an “Overweight” rating.

Market Sentiment and Analyst Recommendations

Bull Case

Regeneron just proved its core franchise still has legs. Dupixent grew 32% in Q4, Eylea HD jumped 66%, and the company beat earnings estimates with $11.44 EPS versus expectations. The pipeline is loaded with at least four FDA approvals expected in 2026, including three new molecular entities, with 18 Phase III studies launching targeting 35,000 patient enrollments. At an 18.94 P/E multiple, the stock trades below historical averages for a biotech with this growth profile and sits well below analyst targets averaging $859.58, with JP Morgan at $950. The balance sheet is fortress-like: $8.61B in cash against $3.45B debt gives real optionality for M&A or shareholder returns. The technical setup shows higher lows and higher highs in an ascending channel with momentum picking up through $780, suggesting the $800 resistance level is breakable.

Bear Case

The headline revenue growth of 2.5% is anemic for a company of this size, even with individual product strength masking broader portfolio weakness. Dupixent and Eylea HD are carrying the entire narrative, creating concentration risk if either product faces competitive pressure or label restrictions. The stock has already gained 14.4% over 52 weeks and sits near all-time highs at $785.65, leaving limited margin of safety for execution misses on those four expected FDA approvals. Regeneron faces intensifying competition in ophthalmology and immunology from cheaper biosimilars and next-generation competitors, which could pressure pricing and margins. The company is heavily dependent on successful Phase III readouts and regulatory approvals to justify current valuations, meaning any clinical setback or delayed approval becomes a significant catalyst for downside. At current levels, you’re paying for perfection on the pipeline.

What to Watch

Monitor the four FDA approvals expected in 2026, particularly timing and label breadth for the three new molecular entities. Any delay or narrower-than-expected approval for these programs would signal execution risk. Track quarterly Dupixent and Eylea HD sales growth rates closely, as deceleration below 20% would suggest market saturation or competitive erosion. Watch for the Q2 2026 FDA decision on the Eylea HD prefilled syringe filler, a seemingly minor event that could expand patient adoption. The February 7 Angiogenesis presentation data on Eylea HD efficacy and safety is a near-term read on clinical differentiation. Keep an eye on the $800 technical resistance level and whether the stock can sustain a breakout above it, as rejection here would suggest profit-taking. Finally, monitor gross margin trends in upcoming earnings reports, as pricing pressure from biosimilars would show up in margin compression before revenue deceleration becomes obvious.

Analyst Consensus

BUY

Based on 26 analyst opinions

Low Target

$730.00

Mean Target

$859.58

High Target

$1057.00

Earnings and Financial Data

Sector

Healthcare

Industry

Biotechnology

Employees

15,410

Earnings & Dividends

Next Earnings

Apr 29, 2026

EPS (Trailing)

$41.47

Dividend Yield

49.0%

Payout Ratio

8.5%

Frequently Asked Questions

Is REGN a good stock to buy?

Regeneron Pharmaceuticals has a price-to-earnings (P/E) ratio of 18.94, which is reasonable for the biotech sector. Analysts recommend a buy with a target price of $859.58, indicating potential upside from the current price of $785.65. This suggests it’s a solid buy right now.

What is REGN’s price target?

The average price target for Regeneron stock among analysts is $859.58. This reflects a potential upside of approximately 9.4% from its current price of $785.65. Investors should consider this positive outlook when making decisions.

Does REGN pay a dividend?

Yes, Regeneron offers a dividend yield of 49.0%, which is unusually high. This can attract income-focused investors while maintaining growth potential in the biotech sector.

What is Regeneron’s market cap?

Regeneron Pharmaceuticals has a market capitalization of $83.05 billion. A market cap of this size indicates a mature company within the healthcare sector, typically paired with stability and growth prospects.

What is the 52-week range for REGN stock?

The 52-week range for Regeneron stock is $476.49 to $821.11. This volatility suggests that the stock has experienced significant price fluctuations, which can present both risks and opportunities for traders.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.